Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 946

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Méjean, Arnaud, Ravaud, Alain, Thezenas, Simon, Colas, Sandra, Beauval, Jean-Baptiste, Bensalah, Karim, Geoffrois, Lionnel, Thiery-Vuillemin, Antoine, Cormier, Luc, Lang, Hervé, Guy, Laurent, Gravis, Gwenaelle, Rolland, Frederic, Linassier, Claude, Lechevallier, Eric, Beisland, Christian, Aitchison, Michael, Oudard, Stephane, Patard, Jean-Jacques, Theodore, Christine, Chevreau, Christine, Laguerre, Brigitte, Hubert, Jacques, Gross-Goupil, Marine, Bernhard, Jean-Christophe, Albiges, Laurence, Timsit, Marc-Olivier, Lebret, Thierry, Escudier, Bernard·2018·New England Journal of Medicine

Abstract

BACKGROUND: Cytoreductive nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies. However, the efficacy of targeted therapies has challenged this standard. We assessed the role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving targeted therapies. METHODS: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with confirmed metastatic clear-cell renal-cell carcinoma at presentation who were suitable candidates for nephrectomy to undergo nephrectomy and then receive sunitinib (standard therapy) or to receive sunitinib alone. Randomization was stratified according to prognostic risk (intermediate or poor) in the Memorial Sloan Kettering Cancer Center prognostic model. Patients received sunitinib at a dose of 50 mg daily in cycles of 28 days on and 14 days off every 6 weeks. The primary end point was overall survival. RESULTS: A total of 450 patients were enrolled from September 2009 to September 2017. At this planned interim analysis, the median follow-up was 50.9 months, with 326 deaths observed. The results in the sunitinib-alone group were noninferior to those in the nephrectomy-sunitinib group with regard to overall survival (stratified hazard ratio for death, 0.89; 95% confidence interval, 0.71 to 1.10; upper boundary of the 95% confidence interval for noninferiority, ≤1.20). The median overall survival was 18.4 months in the sunitinib-alone group and 13.9 months in the nephrectomy-sunitinib group. No significant differences in response rate or progression-free survival were observed. Adverse events were as anticipated in each group. CONCLUSIONS: Sunitinib alone was not inferior to nephrectomy followed by sunitinib in patients with metastatic renal-cell carcinoma who were classified as having intermediate-risk or poor-risk disease. (Funded by Assistance Publique-Hôpitaux de Paris and others; CARMENA ClinicalTrials.gov number, NCT00930033 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1803675

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 946

Metadata

Authors
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., Guy, L., Gravis, G., Rolland, F., Linassier, C., Lechevallier, E., Beisland, C., Aitchison, M., Oudard, S., Patard, J.-J., Theodore, C., Chevreau, C., Laguerre, B., Hubert, J., Gross-Goupil, M., Bernhard, J.-C., Albiges, L., Timsit, M.-O., Lebret, T., & Escudier, B.
Venue
New England Journal of Medicine
Published
2018-08-02
Volume
379
Issue
5
Pages
417-427
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2805060661
Cited by
946
References
11
FWCI
77.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. https://app.cochat.ai/papers/10.1056/nejmoa1803675
The paper
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., Guy, L., Gravis, G., Rolland, F., Linassier, C., Lechevallier, E., Beisland, C., Aitchison, M., Oudard, S., Patard, J.-J., . . . Escudier, B. (2018). Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1803675

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.